Paclitaxel liposomal - Aphios

Drug Profile

Paclitaxel liposomal - Aphios

Alternative Names: Liposome encapsulated paclitaxel - Aphios; Phospholipid nanosomes; Taxosomes

Latest Information Update: 18 Jan 2011

Price : $50

At a glance

  • Originator Aphios Corporation
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 18 Jan 2011 Aphios' paclitaxel liposomal is available for licensing as of 18 Jan 2011. http://www.aphios.com
  • 22 Jun 2009 Paclitaxel liposomal is still in preclinical trials for Breast and ovarian cancers in USA
  • 05 Jul 2004 This compound is still in active development - BIO 2004 Annual International Convention (BIO-2004)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top